India’s pharma exports cross $30-bn in FY25: Industry body chief
India has achieved a significant milestone in its pharmaceutical exports, with the country’s annual drug and pharmaceutical exports touching a record $30.467 billion in FY25. This remarkable achievement has been announced by Pharmaceuticals Export Promotion Council (Pharma EXPO) Director General Raja Bhanu, as reported by The Hindu.
According to official data, pharmaceutical exports in March 2025 saw a significant surge of 31.21% year-on-year (YoY) to reach $3,681.51 million. Moreover, these exports rose by over 9% in FY25, marking a notable increase in the sector. The impressive growth in pharmaceutical exports is a testament to India’s growing reputation as a major pharmaceutical hub, catering to the global demand for high-quality and affordable medicines.
A closer look at the data reveals that exports to the United States (US) saw a notable increase of 14.29% to $8,953.37 million in FY25. This significant growth is a reflection of the country’s strong partnership with the US, which is one of India’s largest pharmaceutical markets. The surge in exports to the US is also a result of the country’s efforts to increase its presence in the global pharmaceutical market, with a focus on quality and compliance with international standards.
The growth in pharmaceutical exports is attributed to several factors, including the country’s large pool of skilled workforce, state-of-the-art manufacturing facilities, and a favorable business environment. India’s pharmaceutical sector has been growing steadily over the years, driven by the government’s initiatives to promote the sector, such as the ‘Pharma Vision 2020’ plan.
Pharma EXPO Director General Raja Bhanu has expressed optimism about the future of India’s pharmaceutical sector, stating that the country is well-positioned to continue its growth momentum. He believes that the sector’s growth will be driven by its ability to innovate, invest in research and development, and meet the evolving needs of the global pharmaceutical market.
The growth in pharmaceutical exports has also created new opportunities for Indian pharmaceutical companies, enabling them to expand their global footprint and increase their market share. This, in turn, has led to increased investment in the sector, with many companies opting to set up new manufacturing facilities or expand existing ones in India.
The government has also taken several steps to promote the pharmaceutical sector, including the introduction of measures to simplify regulatory processes, reduce compliance costs, and increase the availability of raw materials. Additionally, the government has launched initiatives to promote the sector’s growth, such as the ‘Pharmaceuticals and Biotechnology’ component of the ‘Make in India’ initiative.
The growth in pharmaceutical exports has also had a positive impact on the Indian economy, creating new employment opportunities and contributing to the country’s GDP. The sector’s growth has also led to increased investment in research and development, enabling Indian companies to develop new products and processes that can be exported globally.
In conclusion, India’s achievement of crossing the $30-billion mark in pharmaceutical exports in FY25 is a significant milestone for the country’s pharmaceutical sector. The growth in exports is a testament to the sector’s potential and its ability to meet the evolving needs of the global pharmaceutical market. With its large pool of skilled workforce, state-of-the-art manufacturing facilities, and favorable business environment, India is well-positioned to continue its growth momentum in the pharmaceutical sector.
